Pneumonia Vaccine Market Business Opportunities And Regional Outlook 2021

Precision Business Insights published a research report on “Pneumonia Vaccine Market: by Product Type (Prevnar 13, Synflorix, and Pneumovax 23), by Dosage (Single Dose Vial and Pre-filled Syringe), by End User (Child, Adult and Geriatric), by Vaccine Type (Pneumococcal Conjugate Vaccine, and Pneumococcal Polysaccharide Vaccine) and Geography - Global/Region/Country Forecast to 2027”.

Pneumococcal illness can be prevented with the use of the pneumonia vaccination. There are two types of pneumonia vaccines available: PCV13 and PPSV23. The side effects of this vaccine are usually minor and disappear within a few days. Vaccine injections are suggested based on age. PCV13 protects against 13 different forms of pneumococcal bacteria, whereas PPSV23 protects against 23 different types. These vaccines work by helping the body to create antibodies against pneumococcal bacteria, which not only prevent illnesses in the new born but also help prevent infections from spreading to others. Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine are two forms of pneumococcal vaccine. Prevnar 13, Synflorix, and Pneumovax 23 are three types of products offered in this vaccine. Distribution Partner Companies, Non-Governmental Organizations, and Government Authorities are the channels via which pneumonia vaccine is distributed.

View detailed report description here https://precisionbusinessinsights.com/market-reports/global-pneumonia-vaccine-market/

Over the next several years, the pneumonia vaccine market is likely to be driven by rising pneumococcal disease prevalence, significant financial support, and favourable government efforts. Pneumonia is the leading infectious cause of new born death worldwide. Each year, roughly 150 million new cases of pneumonia are diagnosed in children under the age of five around the world. Pneumonia affects children and families, but it is more common in rural regions, with the majority of cases occurring in South Asia and Sub-Saharan Africa. The immune system of a child who is malnourished or undernourished, especially if they are not exclusively breastfed, is weakened. The World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) have collaborated on a Global Action Plan for Pneumonia and Diarrhoea (GAPPD), which aims to accelerate pneumonia control through a mix of initiatives to protect and prevent immunisation. There are a number of constraints and problems that could stymie market expansion. Market limitations are anticipated to be factors such as a lack of awareness among the rural population and the high cost of pneumonia vaccinations.

On the basis of the Vaccine Type, the market is bifurcated into the Pneumococcal Conjugate Vaccine and Pneumococcal Polysaccharide Vaccine. In terms of Product Type, the market is segregated into Synflorix, Prevnar 13, and Pneumovax 23. In terms of Distribution Channel, the market is divided into Non-governmental Organizations, Distribution Partner Companies, and Government Authorities.

With a market share of 34.89 percent in 2020, North America is the leading region in the pneumonia vaccine market. This can be ascribed to the region's well-established infrastructure, significant market participants, and different non-governmental organisations, as well as the region's increasing average life expectancy and median age. However, Asia-Pacific is expected to be the fastest-growing market during the forecast period 2021-2026, owing to the large number of geriatric population in countries such as India and China, as well as a high prevalence of various government initiatives and improved healthcare facilities, which is expected to drive market growth throughout the Pneumonia Vaccine market forecast period 2021-2026.

Request sample report at https://precisionbusinessinsights.com/request-sample?product_id=46307

Some of the major key players in the pneumonia vaccine market are GlaxoSmithKline plc, Pfizer Inc, CSL Ltd, Merck & Co., Inc., Serum Institute of India Pvt. Ltd, Sanofi Pasteur Inc.

Contact:
Mr. Satya
Precision Business InsightsTM | Toll Free: +1 866 598 1553
Email: sales@precisionbusinessinsights.com
Kemp House, 152 – 160 City Road, London EC1V 2NX
Web: https://precisionbusinessinsights.com/ | D U N S® Number: 85278174

About Precision Business Insights:
We are a market research company that strives to provide the highest quality market research insights. Our diverse market research experts are enthusiastic about market research and therefore produce high-quality research reports. We have over 500 clients with whom we have a good business partnership and capacity to provide in-depth research analysis for more than 30 countries. In addition to deliver more than 150 custom solutions, we already have accounts with the top five medical device manufacturers.

Precision Business Insights offers a variety of cost-effective and customized research services to meet particular research requirements. We are a leading research service provider because of our extensive database built by our experts and the services we provide.

This release was published on openPR.